11 Adefovir dipivoxil 10 MG (ADV) for the treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-resistant patients

Outcome of lamivudine resistant hepatitis B virus mutant post‐liver transplantation on lamivudine monoprophylaxis

“…In this series, the two patients (patients 5 and 6) who developed severe hepatitis reactivation secondary to YMDD mutants also responded promptly to adefovir dipivoxil treatment. As adefovir dipivoxil can suppress the replication of YMDD mutants, its potential use as salvage therapy for lamivudine resistant mutants or in combination with lamivudine for viral prophylaxis can be explored (28, 29).…”

Effectiveness of Prophylactic Anti-HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors

“…A recent study of adefovir dipivoxil on patients with chronic HBV related liver cirrhosis and lamivudine resistance in the liver transplantation setting demonstrated a decrease in serum HBV DNA levels by 4 log 10 copies/mL by week 48 of therapy. This reduction in HBV DNA is maintained to week 96 (28). Therefore, further clinical trials with these agents or combination regimens with at least additivity or preferably synergistic effects are warranted in the HSCT setting (29).…”

Disease status and therapeutic end points in hepatitis B

“…In the patients with decompensated disease or post-transplantation receiving open-label combination therapy, HBV-DNA response was seen in 92%. In another study of 196 patients with recurrent hepatitis B post-liver transplantation, adefovir at a dose of 10 mg induced a 3 to 4 log reduction in HBV DNA at 48 weeks [57].…”

“…Dosing intervals should be adjusted in patients with renal insufficiency. Increases in serum creatinine (> 0.5 mg/dL) have been observed in approximately 20% of patients with decompensated cirrhosis and post-liver transplant patients [57]. Therefore, close monitoring is required in these clinical settings when using adefovir.…”